Business
Shortlisted for AIM Awards Technology of the Year
Avacta Group plc announced that its pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award. The AIM Awards celebrate success among the world's fastest-growing publicly quoted companies. The awards event, held annually in London, will take place on October 1, 2025. The pre|CISION® technology changes how potent cancer therapies are delivered to patients, targeting cancer cells while preserving patient vitality. Disclaimer*
About this update from Avacta Group Plc
Avacta's pre|CISION ® Platform Shortlisted for the Technology of the Year Award at the AIM Awards LONDON AND PHILADELPHIA - September 9, 2025 - Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, is pleased to announce today that its pre|CISION ® platform has been shortlisted for the AIM Technology of the Year Award. The AIM Awards is the flagship event for AIM and is held annually, in London, to celebrate success and achievement amongst the world's fastest growing publicly quoted companies. The Awards identify the quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months. The Awards will be distributed at the event on October 1, 2025. Christina Coughlin, CEO of Avacta commented: "We are delighted to be on the shortlist for Technology of the Year among companies listed on the AIM market. Our pre|CISION ® technology changes the way that potent cancer therapies are delivered to patients, where the drug is silent in the bloodstream yet active in the tumor, allowing cancer cells to be targeted while preserving patient vitality. We look forward to the event next month." -Ends- For further information from Avacta, please contact: Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden www.peelhunt.com Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King www.panmureliberum.com www.zeuscapital.co.uk ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert [email protected] Investor Contact Renee Leck THRUST Strategic Communications [email protected] Media Contact Carly Scaduto Carly Scaduto Consulting [email protected] About Avacta - www.avacta.com Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION ® platform. pre|CISION ® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION ® peptide drug conjugates (PDC) or Affimer ® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION ® Platform The pre|CISION ® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION ® platform harnesses this tumor specific protease to cleave pre|CISION ® peptide drug conjugates and pre|CISION ® antibody/Affimer ® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.